Plasma concentrations of advanced glycation end-products and colorectal cancer risk in the EPIC study.


Journal

Carcinogenesis
ISSN: 1460-2180
Titre abrégé: Carcinogenesis
Pays: England
ID NLM: 8008055

Informations de publication

Date de publication:
28 05 2021
Historique:
received: 16 12 2020
revised: 02 03 2021
accepted: 25 03 2021
pubmed: 30 3 2021
medline: 30 9 2021
entrez: 29 3 2021
Statut: ppublish

Résumé

Advanced glycation end-products (AGEs) are a heterogeneous group of compounds formed by the non-enzymatic reaction between amino acids and reducing sugars, or dicarbonyls as intermediate compounds. Experimental studies suggest that AGEs may promote colorectal cancer, but prospective epidemiologic studies are inconclusive. We conducted a case-control study nested within a large European cohort. Plasma concentrations of three protein-bound AGEs-Nε-(carboxy-methyl)lysine (CML), Nε-(carboxy-ethyl)lysine (CEL) and Nδ-(5-hydro-5-methyl-4-imidazolon-2-yl)-ornithine (MG-H1)-were measured by ultra-performance liquid chromatography-tandem mass spectrometry in baseline samples collected from 1378 incident primary colorectal cancer cases and 1378 matched controls. Multivariable-adjusted odds ratios (ORs) and 95% confidence intervals (CIs) were computed using conditional logistic regression for colorectal cancer risk associated with CML, CEL, MG-H1, total AGEs, and [CEL+MG-H1: CML] and [CEL:MG-H1] ratios. Inverse colorectal cancer risk associations were observed for CML (OR comparing highest to lowest quintile, ORQ5 versus Q1 = 0.40, 95% CI: 0.27-0.59), MG-H1 (ORQ5 versus Q1 = 0.73, 95% CI: 0.53-1.00) and total AGEs (OR Q5 versus Q1 = 0.52, 95% CI: 0.37-0.73), whereas no association was observed for CEL. A higher [CEL+MG-H1: CML] ratio was associated with colorectal cancer risk (ORQ5 versus Q1 = 1.91, 95% CI: 1.31-2.79). The associations observed did not differ by sex, or by tumour anatomical sub-site. Although individual AGEs concentrations appear to be inversely associated with colorectal cancer risk, a higher ratio of methylglyoxal-derived AGEs versus those derived from glyoxal (calculated by [CEL+MG-H1: CML] ratio) showed a strong positive risk association. Further insight on the metabolism of AGEs and their dicarbonyls precursors, and their roles in colorectal cancer development is needed.

Identifiants

pubmed: 33780524
pii: 6199858
doi: 10.1093/carcin/bgab026
pmc: PMC8162627
doi:

Substances chimiques

Glycation End Products, Advanced 0
Imidazoles 0
N(6)-carboxyethyllysine 0
Ndelta-(5-hydro-5-methyl-4-imidazolon-2-yl)ornithine 0
N(6)-carboxymethyllysine 70YDX3Z2O7
Ornithine E524N2IXA3
Lysine K3Z4F929H6

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

705-713

Subventions

Organisme : Medical Research Council
ID : MR/N003284/1
Pays : United Kingdom
Organisme : Medical Research Council
ID : G0401527
Pays : United Kingdom
Organisme : Medical Research Council
ID : G1000143
Pays : United Kingdom
Organisme : Cancer Research UK
ID : 14136
Pays : United Kingdom
Organisme : Medical Research Council
ID : MR/M012190/1
Pays : United Kingdom

Informations de copyright

© The Author(s) 2021. Published by Oxford University Press. All rights reserved. For Permissions, please email: journals.permissions@oup.com.

Références

Mol Aspects Med. 2019 Oct;69:2-9
pubmed: 31233770
Br J Cancer. 2018 Nov;119(11):1436-1442
pubmed: 30401889
J Food Sci Technol. 2015 Dec;52(12):7561-76
pubmed: 26604334
Am J Clin Nutr. 2019 Aug 1;110(2):358-366
pubmed: 31240298
J Diabetes Res. 2018 Sep 9;2018:3274084
pubmed: 30271790
Mol Med. 2000 Feb;6(2):114-25
pubmed: 10859028
Ageing Res Rev. 2018 Nov;47:55-66
pubmed: 29969676
Ann N Y Acad Sci. 2005 Jun;1043:111-7
pubmed: 16037229
Atherosclerosis. 2016 Nov;254:291-299
pubmed: 27751506
Cancer Epidemiol. 2016 Jun;42:115-23
pubmed: 27100837
Cancer Lett. 2003 Feb 20;190(2):151-6
pubmed: 12565169
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
Antioxidants (Basel). 2020 Oct 01;9(10):
pubmed: 33019494
BMC Cancer. 2016 Mar 01;16:174
pubmed: 26931562
J Agric Food Chem. 2010 Mar 10;58(5):2966-72
pubmed: 20131787
Oncogene. 2017 Mar;36(11):1559-1572
pubmed: 27669433
Biochem J. 1997 Jun 1;324 ( Pt 2):565-70
pubmed: 9182719
Am J Alzheimers Dis Other Demen. 2006 Jun-Jul;21(3):197-208
pubmed: 16869341
Int J Epidemiol. 2002 Feb;31(1):168-74
pubmed: 11914316
Biochemistry. 2014 May 27;53(20):3327-35
pubmed: 24824951
Lancet Gastroenterol Hepatol. 2019 Dec;4(12):913-933
pubmed: 31648977
Structure. 2011 May 11;19(5):722-32
pubmed: 21565706
Oxid Med Cell Longev. 2020 Mar 18;2020:3818196
pubmed: 32256950
Horm Cancer. 2018 Oct;9(5):295-325
pubmed: 29987748
Food Chem. 2016 Jan 1;190:1145-1150
pubmed: 26213088
Int J Cancer. 2003 May 10;104(6):722-7
pubmed: 12640679
Proc Natl Acad Sci U S A. 1997 Dec 9;94(25):13915-20
pubmed: 9391127
Physiol Res. 2010;59(2):147-156
pubmed: 19537931
J Neuropathol Exp Neurol. 2000 Dec;59(12):1094-105
pubmed: 11138929
J Am Chem Soc. 2012 May 30;134(21):8958-67
pubmed: 22591136
Sci Rep. 2019 Feb 14;9(1):2121
pubmed: 30765817
J Biol Chem. 2008 Oct 3;283(40):27255-69
pubmed: 18667420
Kidney Blood Press Res. 2010;33(1):30-6
pubmed: 20185929
Physiol Rev. 2020 Jan 1;100(1):407-461
pubmed: 31539311
Cancer Epidemiol Biomarkers Prev. 2015 Dec;24(12):1855-63
pubmed: 26404963
Free Radic Biol Med. 2020 May 20;152:516-524
pubmed: 31760091
Public Health Nutr. 2002 Dec;5(6B):1113-24
pubmed: 12639222
Chem Biol Interact. 2011 May 30;191(1-3):322-9
pubmed: 21334317
J Gastroenterol. 2012 Oct;47(10):1073-83
pubmed: 22467055
Ann N Y Acad Sci. 2005 Jun;1043:725-33
pubmed: 16037299
Mol Cell Endocrinol. 2014 Sep;395(1-2):69-78
pubmed: 25111846
Cancer Epidemiol Biomarkers Prev. 2011 Jul;20(7):1430-8
pubmed: 21527578
Biochem J. 2000 Sep 1;350 Pt 2:381-7
pubmed: 10947951
Eur J Nutr. 2020 Oct;59(7):2893-2904
pubmed: 31701336
Cancer Epidemiol Biomarkers Prev. 2021 Jan;30(1):182-192
pubmed: 33082206
Diabetologia. 2016 Sep;59(9):2013-7
pubmed: 27312699
Gastroenterology. 2017 Jun;152(8):1944-1953.e1
pubmed: 28249812
Sci Rep. 2020 May 5;10(1):7596
pubmed: 32371922
J Exp Med. 2008 Feb 18;205(2):275-85
pubmed: 18208974
Clin Nutr. 2018 Jun;37(3):919-925
pubmed: 29381139

Auteurs

Elom K Aglago (EK)

Nutrition and Metabolism Section, International Agency for Research on Cancer, Lyon, France.

Casper G Schalkwijk (CG)

Department of Internal Medicine, CARIM School for Cardiovascular Diseases, Maastricht University Medical Center, Maastricht, The Netherlands.

Heinz Freisling (H)

Nutrition and Metabolism Section, International Agency for Research on Cancer, Lyon, France.

Veronika Fedirko (V)

Department of Epidemiology, Rollins School of Public Health, Emory University, Atlanta, GA, USA.

David J Hughes (DJ)

Cancer Biology and Therapeutics Group (CBT), Conway Institute, School of Biomolecular and Biomedical Science (SBBS), University College Dublin, Dublin, Ireland.

Li Jiao (L)

Department of Medicine, Baylor College of Medicine, Houston, TX, USA.

Christina C Dahm (CC)

Department of Public Health, Aarhus University, Aarhus, Denmark.

Anja Olsen (A)

Department of Public Health, Aarhus University, Aarhus, Denmark.
Danish Cancer Society Research Center, København, Denmark.

Anne Tjønneland (A)

Danish Cancer Society Research Center, København, Denmark.
Department of Public Health, University of Copenhagen, Copenhagen, Denmark.

Verena Katzke (V)

Division of Cancer Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany.

Theron Johnson (T)

Division of Cancer Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany.

Matthias B Schulze (MB)

Department of Molecular Epidemiology, German Institute of Human Nutrition Potsdam-Rehbruecke, Nuthetal, Germany.
Institute of Nutrition Science, University of Potsdam, Nuthetal, Germany.

Krasimira Aleksandrova (K)

Institute of Nutrition Science, University of Potsdam, Nuthetal, Germany.
Nutrition, Immunity and Metabolism Senior Scientist Group, Department of Nutrition and Gerontology, German Institute of Human Nutrition Potsdam-Rehbruecke (DIfE), Nuthetal, Germany.

Giovanna Masala (G)

Cancer Risk Factors and Life-Style Epidemiology Unit, Institute for Cancer Research, Prevention and Clinical Network-ISPRO, Florence, Italy.

Sabina Sieri (S)

Epidemiology and Prevention Unit, Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Milano, Italy.

Vittorio Simeon (V)

Dipartimento di Salute Mentale e Fisica e Medicina Preventiva, University 'Luigi Vanvitelli', Napoli, Italy.

Rosario Tumino (R)

Cancer Registry and Histopathology Department, Provincial Health Authority (ASP 7), Ragusa, Italy.

Alessandra Macciotta (A)

Department of Clinical and Biological Sciences, University of Turin, Torino, Italy.

Bas Bueno-de-Mesquita (B)

Department for Determinants of Chronic Diseases (DCD), National Institute for Public Health and the Environment (RIVM), PO Box 1, 3720 BA Bilthoven, The Netherlands.

Guri Skeie (G)

Faculty of Health Sciences, Department of Community Medicine, University of Tromsø, The Arctic University of Norway, Tromsø, Norway.

Inger Torhild Gram (IT)

Faculty of Health Sciences, Department of Community Medicine, University of Tromsø, The Arctic University of Norway, Tromsø, Norway.

Torkjel Sandanger (T)

Faculty of Health Sciences, Department of Community Medicine, University of Tromsø, The Arctic University of Norway, Tromsø, Norway.

Paula Jakszyn (P)

Unit of Nutrition and Cancer, Cancer Epidemiology Research Programme, Catalan Institute of Oncology, Barcelona, Spain.
Blanquerna School of Health Sciences, Ramon Llull University, Barcelona, Spain.

Maria-Jose Sánchez (MJ)

Escuela Andaluza de Salud Pública (EASP), Granada, Spain.
Instituto de Investigación Biosanitaria ibs.Granada, Granada, Spain.
Department of Preventive Medicine and Public Health, University of Granada, Granada, Spain.
Centro de Investigación Biomédica en Red de Epidemiología y Salud Pública (CIBERESP), Madrid, Spain.

Pilar Amiano (P)

Centro de Investigación Biomédica en Red de Epidemiología y Salud Pública (CIBERESP), Madrid, Spain.
Public Health Division of Gipuzkoa, BioDonostia Research Institute, Donostia-San Sebastian, Spain.

Sandra M Colorado-Yohar (SM)

Centro de Investigación Biomédica en Red de Epidemiología y Salud Pública (CIBERESP), Madrid, Spain.
Department of Epidemiology, Murcia Regional Health Council, IMIB-Arrixaca, Murcia, Spain.
Research Group on Demography and Health, National Faculty of Public Health, University of Antioquia, Medellín, Colombia.

Aurelio Barricarte Gurrea (AB)

Centro de Investigación Biomédica en Red de Epidemiología y Salud Pública (CIBERESP), Madrid, Spain.
Navarra Public Health Institute, Pamplona, Spain.
Navarra Institute for Health Research (IdiSNA), Pamplona, Spain.

Aurora Perez-Cornago (A)

Cancer Epidemiology Unit, Nuffield Department of Population Health, University of Oxford, Oxford, UK.

Ana-Lucia Mayén (AL)

Nutrition and Metabolism Section, International Agency for Research on Cancer, Lyon, France.

Elisabete Weiderpass (E)

Office of the Director, International Agency for Research on Cancer (IARC), Lyon, France.

Marc J Gunter (MJ)

Nutrition and Metabolism Section, International Agency for Research on Cancer, Lyon, France.

Alicia K Heath (AK)

Department of Epidemiology and Biostatistics, School of Public Health, Imperial College London, London, UK.

Mazda Jenab (M)

Nutrition and Metabolism Section, International Agency for Research on Cancer, Lyon, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH